Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Autoimmune Disorders

  Free Subscription


30.08.2021

1 Am J Kidney Dis
1 Ann Neurol
1 Curr Opin Immunol
2 Diabet Med
10 Diabetes
1 Diabetes Res Clin Pract
2 Intern Med
1 J Autoimmun
5 J Immunol
3 J Neuroimmunol
1 J Pediatr
2 J Rheumatol
4 Kidney Int
4 Lancet Neurol
5 Mult Scler
1 Nat Rev Neurol
1 Neurology
1 PLoS Genet
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Kidney Dis

  1. AMIN K, Choksi V, Farouk SS, Sparks MA, et al
    Diarrhea in a Patient With Combined Kidney-Pancreas Transplant.
    Am J Kidney Dis. 2021;78:A13-A16.
    PubMed        


    Ann Neurol

  2. KIMURA K, Lin Y, Yamaguchi H, Sato W, et al
    Th1 - CD11c(+) B cell axis associated with response to plasmapheresis in multiple sclerosis.
    Ann Neurol. 2021 Aug 23. doi: 10.1002/ana.26202.
    PubMed         Abstract available


    Curr Opin Immunol

  3. OIKONOMOU V, Break TJ, Gaffen SL, Moutsopoulos NM, et al
    Infections in the monogenic autoimmune syndrome APECED.
    Curr Opin Immunol. 2021;72:286-297.
    PubMed         Abstract available


    Diabet Med

  4. HOLMAN N, Knighton P, Wild SH, Sattar N, et al
    Cohort profile: National Diabetes Audit for England and Wales.
    Diabet Med. 2021 Jun 1:e14616. doi: 10.1111/dme.14616.
    PubMed         Abstract available

  5. MCGLACKEN-BYRNE SM, Drew SE, Turner K, Peters C, et al
    The SARS-CoV-2 Pandemic Is Associated With Increased Severity Of Presentation Of Childhood Onset Type 1 Diabetes Mellitus: A Multicentre Study Of The First COVID-19 Wave.
    Diabet Med. 2021 Jul 10:e14640. doi: 10.1111/dme.14640.
    PubMed         Abstract available


    Diabetes

  6. RODRIGUEZ-CALVO T, Chen YC, Verchere CB, Haataja L, et al
    Altered beta-Cell Prohormone Processing and Secretion in Type 1 Diabetes.
    Diabetes. 2021 May 4. pii: dbi20-0034. doi: 10.2337/dbi20-0034.
    PubMed         Abstract available

  7. MHANNA V, Fourcade G, Barennes P, Quiniou V, et al
    Impaired Activated/Memory Regulatory T Cell Clonal Expansion Instigates Diabetes in NOD Mice.
    Diabetes. 2021 Jan 21. pii: db20-0896. doi: 10.2337/db20-0896.
    PubMed         Abstract available

  8. ESPES D, Carlsson PO, Selvaraju RK, Rosestedt M, et al
    Longitudinal Assessment of (11)C-5-Hydroxytryptophan Uptake in Pancreas After Debut of Type 1 Diabetes.
    Diabetes. 2021 Jan 21. pii: db20-0776. doi: 10.2337/db20-0776.
    PubMed         Abstract available

  9. BOLDISON J, Thayer TC, Davies J, Wong FS, et al
    Natural Protection From Type 1 Diabetes in Non Obese Diabetic (Nod) Mice is Characterised by a Unique Pancreatic Islet Phenotype.
    Diabetes. 2021 Feb 2. pii: db20-0945. doi: 10.2337/db20-0945.
    PubMed         Abstract available

  10. HERDER C, Maalmi H, Strassburger K, Zaharia OP, et al
    Differences in Biomarkers of Inflammation Between Novel Subgroups of Recent-Onset Diabetes.
    Diabetes. 2021 Feb 19. pii: db20-1054. doi: 10.2337/db20-1054.
    PubMed         Abstract available

  11. LIN A, Mack JA, Bruggeman B, Jacobsen LM, et al
    Low-dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report.
    Diabetes. 2021 Feb 25. pii: db20-1103. doi: 10.2337/db20-1103.
    PubMed         Abstract available

  12. LINSLEY PS, Greenbaum CJ, Nepom GT
    Uncovering Pathways to Personalized Therapies in Type 1 Diabetes.
    Diabetes. 2021;70:831-841.
    PubMed         Abstract available

  13. GREENBAUM CJ
    A Key to T1D Prevention: Screening and Monitoring Relatives as Part of Clinical Care.
    Diabetes. 2021;70:1029-1037.
    PubMed         Abstract available

  14. HAUKKA J, Sandholm N, Valo E, Forsblom C, et al
    Novel Linkage Peaks Discovered for Diabetic Nephropathy in Individuals With Type 1 Diabetes.
    Diabetes. 2021 Jan 7. pii: db20-0158. doi: 10.2337/db20-0158.
    PubMed         Abstract available

  15. ROSS JJ, Wasserfall CH, Bacher R, Perry DJ, et al
    Exocrine Pancreatic Enzymes Are a Serological Biomarker for Type 1 Diabetes Staging and Pancreas Size.
    Diabetes. 2021 Jan 13. pii: db20-0995. doi: 10.2337/db20-0995.
    PubMed         Abstract available


    Diabetes Res Clin Pract

  16. D'ONOFRIO L, Coraggio L, Zurru A, Carlone A, et al
    Short-term safety profile of Sars-Cov2 vaccination on glucose control: continuous glucose monitoring data in people with autoimmune diabetes.
    Diabetes Res Clin Pract. 2021 Aug 24:109022. doi: 10.1016/j.diabres.2021.109022.
    PubMed         Abstract available


    Intern Med

  17. TAIRA M, Matsumura T, Sumita Y, Moriyama M, et al
    A Rare Case of Acute Fibrinous and Organizing Pneumonia Associated with Systemic Lupus Erythematosus and Autoimmune-associated Hemophagocytic Syndrome: The Involvement of CD163-positive Macrophages.
    Intern Med. 2021 Aug 24. doi: 10.2169/internalmedicine.7184.
    PubMed         Abstract available

  18. KAKUMOTO T, Kobayashi S, Yuuki H, Kainaga M, et al
    Cranial Nerve Involvement and Dysautonomia in Post-COVID-19 Guillain-Barre Syndrome.
    Intern Med. 2021 Aug 24. doi: 10.2169/internalmedicine.7355.
    PubMed         Abstract available


    J Autoimmun

  19. RELA M, Jothimani D, Vij M, Rajakumar A, et al
    Auto-immune hepatitis following COVID vaccination.
    J Autoimmun. 2021;123:102688.
    PubMed         Abstract available


    J Immunol

  20. NANDEDKAR-KULKARNI N, Esakov E, Gregg B, Atkinson MA, et al
    Insulin Receptor-Expressing T Cells Appear in Individuals at Risk for Type 1 Diabetes and Can Move into the Pancreas in C57BL/6 Transgenic Mice.
    J Immunol. 2021 Mar 3. pii: jimmunol.1900357. doi: 10.4049/jimmunol.1900357.
    PubMed         Abstract available

  21. PAN W, Nagpal K, Suarez-Fueyo A, Ferretti A, et al
    The Regulatory Subunit PPP2R2A of PP2A Enhances Th1 and Th17 Differentiation through Activation of the GEF-H1/RhoA/ROCK Signaling Pathway.
    J Immunol. 2021;206:1719-1728.
    PubMed         Abstract available

  22. LANGRISH CL, Bradshaw JM, Francesco MR, Owens TD, et al
    Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease.
    J Immunol. 2021;206:1454-1468.
    PubMed         Abstract available

  23. CHIKUMA S, Yamanaka S, Nakagawa S, Ueda MT, et al
    TRIM28 Expression on Dendritic Cells Prevents Excessive T Cell Priming by Silencing Endogenous Retrovirus.
    J Immunol. 2021;206:1528-1539.
    PubMed         Abstract available

  24. LIN X, Tawch S, Wong HT, Roy S, et al
    Nrf2 through Aryl Hydrocarbon Receptor Regulates IL-22 Response in CD4(+) T Cells.
    J Immunol. 2021;206:1540-1548.
    PubMed         Abstract available


    J Neuroimmunol

  25. HABEK M, Jakob Brecl G, Basic Kes V, Rogic D, et al
    Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study.
    J Neuroimmunol. 2021;359:577696.
    PubMed         Abstract available

  26. RIBES GARCIA S, Casanova Estruch B, Gomez Pajares F, Juan Blanco MA, et al
    Prognostic utility of the IgM oligoclonal bands against myelin lipids in multiple sclerosis.
    J Neuroimmunol. 2021;359:577698.
    PubMed         Abstract available

  27. COSSU D, Yokoyama K, Sato S, Noda S, et al
    PARKIN modifies peripheral immune response and increases neuroinflammation in active experimental autoimmune encephalomyelitis (EAE).
    J Neuroimmunol. 2021;359:577694.
    PubMed         Abstract available


    J Pediatr

  28. IKLE JM, Maahs DM
    50 Years Ago in TheJournalofPediatrics: Progress in Pediatric Diabetes Prediction, Management, and Outcomes.
    J Pediatr. 2021;233:131.
    PubMed        


    J Rheumatol

  29. BERTI A, Specks U
    The Survival of Patients With Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody-associated Vasculitis.
    J Rheumatol. 2021;48:314-317.
    PubMed        

  30. JAYNE D
    Antineutrophil Cytoplasmic Antibody-associated Vasculitis Management 2020: Where Are We Now?
    J Rheumatol. 2021;48:479-481.
    PubMed        


    Kidney Int

  31. HUERTA A, Caballero Bermejo AF, de Villa LF, Sedano R, et al
    Measurement of the passage of mycophenolic acid into breast milk in a patient with lupus nephritis.
    Kidney Int. 2021;100:711.
    PubMed        

  32. SALHI S, Ribes D, Colombat M, Fortenfant F, et al
    Bortezomib plus dexamethasone for rituximab-resistant PLA2R(+) membranous nephropathy.
    Kidney Int. 2021;100:708-709.
    PubMed        

  33. BORZA DB
    Fumarate in membranous nephropathy: more questions than answers.
    Kidney Int. 2021;100:707.
    PubMed        

  34. GUEGUEN L, Loheac C, Saidani N, Khatchatourian L, et al
    Membranous nephropathy following anti-Covid-19 mRNA vaccination.
    Kidney Int. 2021 Aug 19. pii: S0085-2538(21)00757.
    PubMed        


    Lancet Neurol

  35. CORREALE J
    BTK inhibitors as potential therapies for multiple sclerosis.
    Lancet Neurol. 2021;20:689-691.
    PubMed        

  36. CALABRESI PA
    Trials and tribulations on the path to remyelination.
    Lancet Neurol. 2021;20:686-687.
    PubMed        

  37. REICH DS, Arnold DL, Vermersch P, Bar-Or A, et al
    Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
    Lancet Neurol. 2021;20:729-738.
    PubMed         Abstract available

  38. BROWN JWL, Cunniffe NG, Prados F, Kanber B, et al
    Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study.
    Lancet Neurol. 2021;20:709-720.
    PubMed         Abstract available


    Mult Scler

  39. ALONSO R, Galleguillos L
    Dengue fever in a multiple sclerosis patient taking ocrelizumab: Clinical commentary.
    Mult Scler. 2021 Aug 27:13524585211039750. doi: 10.1177/13524585211039750.
    PubMed        

  40. GUERRA T, Bollo L, Trojano M, Iaffaldano P, et al
    Dengue fever in a multiple sclerosis patient taking Ocrelizumab.
    Mult Scler. 2021 Aug 27:13524585211030214. doi: 10.1177/13524585211030214.
    PubMed         Abstract available

  41. COHEN JA, Cameron MH, Goldman MD, Goodman AD, et al
    A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.
    Mult Scler. 2021 Aug 27:13524585211035333. doi: 10.1177/13524585211035333.
    PubMed         Abstract available

  42. BLASCHKE SJ, Ellenberger D, Flachenecker P, Hellwig K, et al
    Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry.
    Mult Scler. 2021 Aug 27:13524585211039753. doi: 10.1177/13524585211039753.
    PubMed         Abstract available

  43. CONWAY DS, Marck CH
    Comorbidities require special attention in minorities with multiple sclerosis.
    Mult Scler. 2021 Aug 27:13524585211037578. doi: 10.1177/13524585211037578.
    PubMed        


    Nat Rev Neurol

  44. LUNEMANN JD
    Getting specific: targeting Fc receptors in myasthenia gravis.
    Nat Rev Neurol. 2021 Aug 23. pii: 10.1038/s41582-021-00547.
    PubMed        


    Neurology

  45. KOCH MW, Mostert JP, Wolinsky JS, Lublin FD, et al
    Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2021 Aug 25. pii: WNL.0000000000012690.
    PubMed         Abstract available


    PLoS Genet

  46. PARK K, Ryoo J, Jeong H, Kim M, et al
    Aicardi-Goutieres syndrome-associated gene SAMHD1 preserves genome integrity by preventing R-loop formation at transcription-replication conflict regions.
    PLoS Genet. 2021;17:e1009523.
    PubMed         Abstract available


    PLoS One

  47. GOODIN DS, Khankhanian P, Gourraud PA, Vince N, et al
    The nature of genetic and environmental susceptibility to multiple sclerosis.
    PLoS One. 2021;16:e0246157.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: